We are so proud that Dr. David Sommerhalder has been selected as a 2025 Health Care Hero in the Medical Research Category by the San Antonio Business Journal. Read more here (subscription required)
Alterome Doses First Patient in Phase 1 Study of ALTA3263, a Novel Pan-KRAS Dual ON/OFF Inhibitor, in Advanced Solid Tumors
ALTA3263 is a potential best-in-class KRAS-selective small molecule inhibitor that potently targets >90% of KRAS mutations. Read More
Iambic Completes Dose Escalation in Ongoing Phase 1/1B Study of Lead Program IAM1363, a Small Molecule Inhibitor of Wild-Type and Oncogenic HER2 Mutant Proteins
Designed with Iambic’s AI-Drug Discovery platform, IAM1363 is highly differentiated by its target selectivity, brain-penetrance, pan-mutant activity, and tumor enrichment. Read More
Avenzo Therapeutics Initiates Phase 1/2 Clinical Study of AVZO-1418, a Potential Best-in-Class, Novel EGFR/HER3 Bispecific Antibody-Drug Conjugate
Avenzo Therapeutics, Inc. (“Avenzo”), a clinical-stage biotechnology company developing next-generation oncology therapies, today announced initiation of a Phase 1/2 clinical study of its potential best-in-class EGFR/HER3 bispecific antibody-drug conjugate, AVZO-1418, in patients with advanced solid tumors. Read More
NEXT Oncology Names Dr. Alex Spira Chief Scientific Officer
Dr. Spira to lead scientific and research strategy, advancing Phase 1 oncology trials. SAN ANTONIO, TX – May 20, 2025 – NEXT Oncology, one of the world’s largest Phase 1 cancer clinical trial centers, has appointed Alex Spira, MD, PhD, FACP, its new Chief Scientific Officer. Dr. Spira, who currently leads NEXT Oncology – Virginia, will now oversee the company’s …
Crown Bioscience and NEXT Oncology Cement Partnership Extension
Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and part of JSR Life Sciences and Japan-based JSR Corporation, is pleased to announce the extension of its partnership with NEXT Oncology, one of the world’s largest Phase I Oncology Clinical Trial networks. Read More
Tagworks Pharmaceuticals Announces FDA Clearance of IND Application and Initiation of Phase 1 Clinical Trial for TGW101 and Appoints Keith Orford, MD, PhD, as Chief Medical Officer
Tagworks Pharmaceuticals BV (“Tagworks”), a clinical-stage precision oncology company using its proprietary Click-to-Release treatment platform to develop a new standard of care for patients suffering from solid tumors, today announced the U.S. Food and Drug Administration (FDA) cleared the investigational new drug (IND) application for a Phase 1 clinical trial evaluating TGW101, a first-in-class antibody drug-conjugate (ADC) targeting tumor associated …
Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors
Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing. Read More
NEXT Oncology Opens Newest Phase 1 Clinical Trial Center in Houston, Texas
With continued global expansion plans, NEXT Oncology is one of the largest Phase 1 Cancer Trial organizations in the world. (SAN ANTONIO, TX) March 25, 2025 ––NEXT Oncology has opened its seventh cancer care center in Houston, Texas as part of the company’s global growth initiative. NEXT – Houston, which will be led by Dr. Peter DeMaria and Dr. Jennifer …
Innate Pharma Announces First Patient Dosed in Phase 1 Study of Its Nectin-4 Targeting Antibody Drug Conjugate IPH4502 in Selected Advanced Solid Tumors
IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4. Read More